Daily Archives: August 14, 2022

Accelerated approval is granted by FDA to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

August 14th, 2022 Lung cancer

August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Admin.... Read More

Capmatinib is approved for metastatic non-small cell lung cancer

August 14th, 2022 Lung cancer

August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Admin.... Read More

Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer

August 14th, 2022 Prostrate cancer

August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).ARASENS (NC.... Read More

Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer

August 14th, 2022 Drugs

August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting or experienced a disease recurrence during or within six months of fini.... Read More